5 Amerena J, et al. ABPM comparison of the anti-hypertensive profile of telmisartan and enalapril surrounded via patients subsequent to mild-to-moderate obligatory hypertension. J Int Med Res 2002; 30(6):543-552.
6 Chobanian AV, et al. The Seventh Report of the Joint National Committee by the side of Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289(19): 2560-2572.
7 Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines in support of the direction of arterial hypertension. J Hypertens 2003; 21(6):1011-1053.
8 Parving HH, et al. The effect of irbesartan on the beginning of diabetic nephropathy in patients with strain 2 diabetes. N Engl J Med 2001: 345:870-8 9 Viberti G, et al. Microalbuminuria contraction with valsartan in patients with type 2 diabetes mellitus: a blood strain self-sufficient effect. Circulation 2002; 106: 672-8 10 Brenner BM, et al. Effects of losartan on renal and cardiovascular outcome in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
11 Lewis EJ, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy in the red to type 2 diabetes. N Engl J Med 2001: 345: 851-60.
12 Vogt L, et al. Effects of telmisartan versus hydrochlorothiazide on albumin excretion in isolated systolic hypertension. A sub-study from the ARAMIS be trained. American Society of Nephrology 2002.
13 Redón J, et al. Renin-angiotensin plot gene polymorphisms: similarity with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Phamacogenomics J 2004; In forecast.
14 Cupisti A, et al. Effect of telmisartan on the proteinuria and circadian blood pressure profile in incorrigible renal patients. Biomed Pharmacother 2003; 57(3-4):169-172.
15 Hannedouche T, et al, on behalf of the French Collaborative Telmisartan Study Group. Evaluation of the sanctuary and efficacy of telmisartan and enalapril, with the hand over an undertaking bright site of frusemide, in moderate-renal let-down patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001; 2(4):246-254.
They treat 93 patients who have liberal, locally advanced or metastatic, radioiodine-resistant differentiate thyroid cancer with a all daylight oral dose of 125 mg of motesanib diphosphate and well-dressed for sovereign radiographic vdu of tumor spread.
Cardionephrology 8. Italy: Editoriale Bios, 2004.
17 Ucak S, et al. Combination of telmisartan and ACE-I by a long chalk reduce urinary albumin excretion in hypertensive patients with type 2 diabetes. Program and abstract of the 38th Annual Meeting of the European Association for the Study of Diabetes Budapest, Hungary: September 1-5, 2002. 18 Weber M. The telmisartan Programme of Research tO engagement Telmisartan End-organ proteCTION (PROTECTION). J Hypertens 2003;21 (Suppl 6):S37-S46.
Read more about pills price
No comments:
Post a Comment